MC-Val-Cit-PAB-DX8951|CAS 2504068-28-2|DC Chemicals

Cas No.:	2504068-28-2
Chemical Name:	MC-Val-Cit-PAB-DX8951
SMILES:	O=C1[C@](O)(CC)C2C=C3C4C(CN3C(C=2CO1)=O)=C1C2=C(C(=C(C=C2N=4)F)C)CC[C@@H]1NC(OCC1C=CC(NC(=O)[C@H](CCCNC(=O)N)NC([C@H](C(C)C)NC(CCCCCN2C(=O)C=CC2=O)=O)=O)=CC=1)=O
Formula:	C₅₃H₆₀FN₉O₁₂
M.Wt:	1034.10
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC74470	SuO-Val-Cit-PAB-MMAE	A drug-linker conjugate for antibody-drug conjugate by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the cleavable peptide SuO-Val-Cit-PAB..
DC72532	Fmoc-VAP-MMAE	Fmoc-VAP-MMAE is a drug-linker conjugates for ADC. Fmoc-VAP-MMAE consists of an ADC linker and a tubulin inhibitor MMAE, with a protective Fmoc group.
DC72119	Deruxtecan analog 2	Deruxtecan analog 2 (example 9 P3) is a Deruxtecan analog. Deruxtecan analog 2 is a drug-linker conjugate composed of Camptothecin and a linker. Camptothecin (CPT) is a Topo I inhibitor with antineoplastic activity against colorectal, breast, lung and ovarian cancers. Deruxtecan analog 2 can be used for the preparation anti-FGFR2 ADC.
DC71950	Ac-Lys-Val-Cit-PABC-MMAE	Ac-Lys-Val-Cit-PABC-MMAE is a drug-linker conjugate for ADC. Ac-Lys-Val-Cit-PABC-MMAE contains the ADC linker (peptide Ac-Lys-Val-Cit-PABC) and a potent tubulin polymerization inhibitor MMAE.
DC71666	MC-VA-PABC-MMAE	MC-VA-PABC-MMAE is a drug-linker conjugate for ADC. MC-VA-PABC-MMAE contains the ADCs linker (peptide MC-VA-PABC) and a potent tubulin polymerization inhibitor MMAE.
DC71665	Val-Cit-PAB-MMAF	Val-Cit-PAB-MMAF is a drug-linker conjugate for ADC. Val-Cit-PAB-MMAF contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin polymerization inhibitor MMAF.
DC71664	Val-Cit-PAB-MMAF sodium	Val-Cit-PAB-MMAF sodium is a drug-linker conjugate for ADC. Val-Cit-PAB-MMAF sodium contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin polymerization inhibitor MMAF.
DC71115	SN38 NHS ester	SN38 NHS ester is the NHS ester derivative of SN38. SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis. SN38 NHS ester can be used for the synthesis of antibody-drug conjugates (ADCs).
DC50214	MC-Val-Cit-PAB-DX8951	MC-Val-Cit-PAB-DX8951 is a drug-linker conjugate for ADC. MC-Val-Cit-PAB-DX8951 is composed of a DNA topoisomerase I DX-8951 and a cathepsin cleavable ADC linker.
DC48385	MC-VC-PABC-amide-PEG1-CH2-CC-885	MC-VC-PABC-amide-PEG1-CH2-CC-885 is an Antibody-Drug Conjugates (ADC) based on protein degrading agent (protac molecular glue, etc.).